Allied Market Research


Canada Oncology Drugs Market

Canada Oncology Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report, by Therapy Modality and, by Cancer Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Oncology drugs help in the prevention, diagnosis, and treatment of cancer. It includes chemotherapy drugs, hormone therapy drugs such as Tamoxifen (brand name Nolvadex), immunotherapy drugs, and other drugs such as bosulif (bosutinib), bosutinib, brentuximab vedotin and brigatinib that are used in the treatment of cancer. According to the CDC, 21.1 million adults were diagnosed with cancer in 2015. This shows the immediate need of the rise in the number of oncologic drugs in the market. Around 206,200 new cases of cancer (equal number of men and women) are expected to be diagnosed in Canada in 2017. Half of these (103,200 cases) will include lung, breast, colorectal, and prostate cancers.

Increase in prevalence of cancer, rise in the population, and growth in awareness about the availability of cancer treatments predominantly drive the market growth. However, the high cost involved in new drug development coupled with threat of failure and adverse effects associated with anti-cancer drug therapies are projected to restrain the growth of the Canada oncology drug market. Nevertheless, advancement of cancer drug research owing to biological/targeted therapies and personalized medicines hold promising opportunities for pharmaceutical, bio-pharmaceutical, and biotechnology companies engaged in developing cancer drugs.

The Canada oncology drugs market is segmented on the basis of therapy modality and types of cancer. Based on therapy modality, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy, and others. In terms of types of cancer, the market is classified into blood cancer, breast cancer, gastrointestinal cancer, respiratory/lung cancer, skin cancer, and others.
The companies operating in the market are AstraZeneca Plc. GlaxoSmithKline, Eli lilly & Co., Roche diagnostics, Novartis AG, Pfizer Inc., Merck & Co., Gilead, Sanofi S.A, and Celgene Corporation.

Key Benefits

  • The study provides an in-depth analysis of the Canada oncology drugs market along with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates the various forms of available oncology drugs.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.
  • The projections in this report are made by analyzing the current trends and future market potential  in terms of value.

Canada Oncology Drugs Market Report Highlights

Aspects Details
By Therapy Modality
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
By Cancer Type
  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Respiratory/Lung Cancer
  • Skin Cancer
  • Others
By Region
  • Canada 
Key Market Players

Merck & Co., Pfizer Inc., Eli lilly & Co., Novartis AG, Sanofi S.A., Roche diagnostics, GlaxoSmithKline, Celgene Corporation, Gilead, AstraZeneca Plc.

Loading Table Of Content...

Canada Oncology Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032